STOCK TITAN
  1. Home
  2. SEC Filings
  3. IRMD
  4. [8-K] IRADIMED CORP Reports Material Event

IRADIMED sets 2026 revenue outlook at $91.6M–$93.1M

Management expects fourth-quarter revenue of $25.0 million to $26.5 million; the board declared a $0.20 quarterly dividend payable November 27, 2026.

Filing Impact
(High)
Filing Sentiment

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment worksHow the balance works

Form Type
8-K

Rhea-AI Filing Summary

IRADIMED CORPORATION reported third-quarter 2026 revenue of $24.2 million, up 14% from $21.2 million a year earlier. Net income increased 17% to $6.5 million; GAAP diluted EPS was $0.51 versus $0.43, and non-GAAP diluted EPS was $0.55 versus $0.47. Cash flow from operations was $7.0 million, consistent with the prior-year quarter.

For the first nine months of 2026, revenue was $66.6 million, up 9%, and cash flow from operations was $21.2 million, up 12%. The company expects fourth-quarter revenue of $25.0 million to $26.5 million, GAAP diluted EPS of $0.53 to $0.57, and non-GAAP diluted EPS of $0.57 to $0.61. Full-year guidance was revised to revenue of $91.6 million to $93.1 million, GAAP diluted EPS of $1.90 to $1.94, and non-GAAP diluted EPS of $2.07 to $2.11.

The board declared a regular quarterly cash dividend of $0.20 per share, payable November 27, 2026, to stockholders of record November 13, 2026.

3 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 0 points

How the balance works

Positive

  • Moderate pointQ3 revenue increased 14% to $24.2 million year over year.
  • Moderate pointQ3 net income increased 17% to $6.5 million year over year.
  • Moderate pointNine-month operating cash flow increased 12% to $21.2 million.

Negative

  • None.

Filing Explained

For the completed third quarter, IRADIMED reported gross profit margin of 76%, down from 78% in the year-earlier quarter, even as revenue rose year over year.

Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Q3 revenue $24.2 million; $21.2 million Three months ended September 30, 2026 and 2025
Q3 net income $6.5 million; $5.6 million Three months ended September 30, 2026 and 2025
GAAP diluted EPS $0.51; $0.43 Third quarter 2026 compared with third quarter 2025
Non-GAAP diluted EPS $0.55; $0.47 Third quarter 2026 compared with third quarter 2025
Nine-month revenue $66.6 million; $61.1 million Nine months ended September 30, 2026 and 2025
Operating cash flow $21.2 million; $19.0 million Nine months ended September 30, 2026 and 2025
Fourth-quarter revenue guidance $25.0 million to $26.5 million Fourth quarter 2026
Quarterly cash dividend $0.20 per share Payable November 27, 2026, to stockholders of record November 13, 2026
Non-GAAP financial measures financial
"These non-GAAP financial measures are not prepared in accordance"
Non-GAAP financial measures are numbers companies use to show their financial performance that exclude certain expenses or income. They help investors see how the company might perform without one-time costs or other unusual items, giving a different perspective from official reports. However, since they can be adjusted, they don’t always tell the full story and should be looked at alongside standard financial figures.
Free cash flow financial
"We calculate free cash flow as net cash provided by operating activities"
Free cash flow is the amount of money a company has left over after paying all its expenses and investing in its business, like buying equipment or updating facilities. It shows how much cash is available to reward shareholders, pay down debt, or save for future growth. This helps investors understand if a company is financially healthy and able to grow.
Stock-based compensation expense financial
"excludes stock-based compensation expense, net of tax benefit"
Stock-based compensation expense is the value that a company records when it gives employees or executives shares or options to buy shares as part of their pay. It matters because it shows the true cost of paying employees this way, which can affect the company's profits and how investors see its financial health.
Deferred revenue financial
"Deferred revenue, non-current"
Cash a company has already received for goods or services it has promised but not yet delivered; it's recorded as a liability because the company still owes that product, service, or future revenue recognition. For investors, deferred revenue signals upcoming work or deliveries that will convert into reported sales over time and affects short-term obligations, cash flow quality, and how quickly a firm can grow recognized revenue—think of it like prepaid subscriptions or gift cards a business must honor later.
Revenue $24.2 million 14% increase compared with the same period in 2025
Net income $6.5 million 17% increase compared with the same period in 2025
GAAP diluted EPS $0.51 Compared with $0.43 in the same period in 2025
Non-GAAP diluted EPS $0.55 Compared with $0.47 in the same period in 2025
Guidance

Fourth quarter 2026: revenue of $25.0 million to $26.5 million, GAAP diluted EPS of $0.53 to $0.57, and non-GAAP diluted EPS of $0.57 to $0.61. Full-year 2026: revenue of $91.6 million to $93.1 million, GAAP diluted EPS of $1.90 to $1.94, and non-GAAP diluted EPS of $2.07 to $2.11.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much revenue did IRMD report for the third quarter of 2026?
IRADIMED reported third-quarter 2026 revenue of $24.2 million, up 14% from $21.2 million in the third quarter of 2025. Net income was $6.5 million, up 17% year over year.

How did IRMD revise its full-year 2026 guidance?
IRADIMED revised full-year 2026 revenue guidance to $91.6 million to $93.1 million from $91.0 million to $96.0 million; GAAP diluted EPS to $1.90 to $1.94 from $1.90 to $2.05; and non-GAAP diluted EPS to $2.07 to $2.11 from $2.06 to $2.21.

What dividend did IRMD declare, and when is it payable?
The board declared a regular quarterly cash dividend of $0.20 per share, payable November 27, 2026, to stockholders of record as of November 13, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Available on EDGAR Accepted by SEC EDGAR
0001325618FALSE00013256182026-10-302026-10-30

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
Date of report (Date of earliest event reported): October 30, 2026
IRADIMED CORPORATION
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation)
001-3653473-1408526
(Commission File Number)(IRS Employer Identification No.)
12705 Ingenuity Drive, Orlando, Florida
32826
(Address of principal executive offices)(Zip Code)
(407) 677-8022
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Securities registered pursuant to Section 12(b) of the Act:
Title of each class:Trading SymbolName of each exchange on which registered:
Common stock, par value $0.0001IRMDNASDAQ Global Market


Item 2.02            Results of Operations and Financial Condition.
On October 30, 2026, IRADIMED CORPORATION issued a press release (the “Press Release”) announcing its financial results for the quarter ended September 30, 2026. A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that Section. Furthermore, such information, including Exhibit 99.1, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01            Financial Statements and Exhibits.
(d)Exhibits
Exhibit No.Description
99.1
Press release dated October 30, 2026.
104Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
IRADIMED CORPORATION
Date: October 30, 2026
By: /s/John Glenn
Name: John Glenn
Title: Chief Financial Officer


Exhibit 99.1
irmd1.jpg
IRADIMED CORPORATION Reports Third Quarter 2026 Financial Results
Announces Regular Quarterly Cash Dividend of $0.20 Per Share


•Reports revenue of $24.2 million for the third quarter of 2026, which increased by $3.0 million, or 14% compared to the same period in 2025 and increased by $3.7 million or 18% compared to the second quarter of 2026.
•Reports GAAP diluted EPS of $0.51 and non-GAAP diluted EPS of $0.55 for the third quarter of 2026 compared to GAAP diluted EPS of $0.41 and non-GAAP diluted EPS of $0.47 for the second quarter of 2026.
•Declares a regular quarterly cash dividend of $0.20 per share of common stock for the third quarter of 2026, payable on November 27, 2026.
Orlando, Florida, October 30, 2026 – IRADIMED CORPORATION (the “Company” or “Iradimed”) (NASDAQ: IRMD) announced today its financial results for the three and nine months ended September 30, 2026. The Company is a leader in developing innovative magnetic resonance imaging (“MRI”) compatible medical devices and products. The Company is a provider of (i) non-magnetic intravenous (“IV”) infusion pump systems and (ii) a non-magnetic patient vital signs monitoring system that are each designed for use during MRI procedures.
“We are pleased to report record revenue of $24.2 million for the third quarter, driven by the continued successful launch of our new 3870 MR IV pump. As our manufacturing team gains experience with the new platform while at the same time greatly ramping up production, we began realizing the efficiencies we anticipated with gross margin improving sequentially as expected. Quarterly bookings also set new records, driven by another record number of monitor units being booked and a 45% year-over-year increase in domestic pump channels booked. Of special note is that over 70% of pump bookings in the quarter were for our ‘quad stack’ configuration of four pumps on a single IV pole, as customers continue to accelerate their replacement of our older model and standardize on this setup which is a doubling of pump channels previously available at each MRI. With record bookings and rapidly building 3870 momentum, we believe we are well positioned for a strong finish to the year,” said Roger Susi, President and Chief Executive Officer of Iradimed.

“For the fourth quarter of 2026, we expect revenue of $25.0 million to $26.5 million, attaining a $100.0 million revenue run rate while generating GAAP diluted earnings per share of $0.53 to $0.57 and non-GAAP diluted earnings per share of $0.57 to $0.61. We revise our guidance for the full-year 2026, expecting to report revenue of $91.6 million to $93.1 million from $91.0 million to $96.0 million, and GAAP diluted earnings per share to $1.90 to $1.94 from $1.90 to $2.05 and non-GAAP diluted earnings per share to $2.07 to $2.11 from $2.06 to $2.21,” added Mr. Susi.

The Company’s board of directors declared a regular quarterly cash dividend of $0.20 per share of our outstanding common stock. The dividend is payable to stockholders of record as of the close of business on November 13, 2026 and will be paid on November 27, 2026.

Three Months Ended September 30, 2026

For the three months ended September 30, 2026, the Company reported revenue of $24.2 million, compared to $21.2 million for the comparable period of 2025, which increased by $3.0 million or 14%. The Company reported net income of $6.5 million, compared to $5.6 million for the comparable period of 2025, which increased by 17%. Earnings per share increased by $0.08 per diluted share or 17% to $0.51 per diluted share, for the three months ended September 30, 2026, compared to $0.43 per diluted share for the same period of 2025.


For the three months ended September 30, 2026, non-GAAP net income was $7.1 million, an increase of 17% compared to $6.1 million for the same period in 2025. Non-GAAP net income excludes stock-based compensation expense, net of tax benefit, of $0.6 million for the third quarter of 2026 and $0.5 million for the third quarter of 2025. On a non-GAAP basis, net income per diluted share was $0.55 for the three months ended September 30, 2026, compared to $0.47 per diluted share for the comparable period of 2025, which increased by 17%.

Nine Months Ended September 30, 2026

For the nine months ended September 30, 2026, the Company reported revenue of $66.6 million, compared to $61.1 million for the comparable period of 2025, which increased by $5.5 million or 9%. The Company reported net income of $17.5 million, compared to $16.0 million for the comparable period of 2025, which increased by 9%. Earnings per share increased by $0.12 per diluted share or 10% to $1.37 per diluted share, for the nine months ended September 30, 2026, compared to $1.25 per diluted share for the same period of 2025.

For the nine months ended September 30, 2026, non-GAAP net income was $19.3 million, an increase of 9% compared to $17.8 million for the same period in 2025. Non-GAAP net income excludes stock-based compensation expense, net of tax benefit, of $1.8 million for each of the nine-month periods presented. On a non-GAAP basis, net income per diluted share was $1.50 for the nine months ended September 30, 2026, compared to $1.39 per diluted share for the comparable period of 2025, which increased by 8% .


Revenue Information:

Three Months Ended
September 30,		Nine Months Ended
September 30,
2026202520262025
(in thousands)(unaudited)(unaudited)
Devices:
MRI Compatible Intravenous ("IV") Infusion Pump Systems$8,687 $8,334 $22,779 $22,521 
MRI Compatible Patient Vital Signs Monitoring Systems8,006 6,872 21,778 19,361 
Ferro Magnetic Detection Systems483 378 1,861 1,278 
Total devices revenue17,176 15,584 46,418 43,160 
Amortization of extended maintenance agreements801 613 2,218 1,766 
Disposables4,981 4,131 14,659 13,281 
Services and other1,245 874 3,353 2,915 
Total revenue$24,203 $21,202 $66,648 $61,122 


For the three months ended September 30, 2026 and 2025, domestic sales were 82% and 85% of total revenue, respectively. For the three months ended September 30, 2026, the gross profit margin was 76% compared to 78% for the comparable period of 2025.
For the nine months ended September 30, 2026 and 2025, domestic sales were 82% and 85% of total revenue, respectively. For the nine months ended September 30, 2026, the gross profit margin was 76% compared to 77% for the comparable period of 2025.

Cash Flow from Operations

For the three months ended September 30, 2026, cash flow from operations was $7.0 million, consistent with $7.0 million for the comparable period of 2025. For the three months ended September 30, 2026, cash provided by operations reflected higher net income and a smaller increase in accounts receivable, partially offset by higher income tax payments, increased inventory purchases, and prepaid expenses.. See the compilation of non-GAAP free cash flow in the table later in this release.


For the nine months ended September 30, 2026, cash flow from operations was $21.2 million, compared to $19.0 million for the comparable period of 2025, an increase of 12%. For the nine months ended September 30, 2026, cash provided by operations reflected higher net income, a smaller increase in accounts receivable, and higher accounts payable, partially offset by higher income tax payments, increased inventory purchases, and a smaller increase in deferred revenue. See the compilation of non-GAAP free cash flow in the table later in this release.
Financial Guidance
For the fourth quarter of 2026, the Company expects revenue of $25.0 million to $26.5 million, GAAP diluted earnings per share of $0.53 to $0.57, and non-GAAP diluted earnings per share of $0.57 to $0.61. For the full year 2026, the Company expects to report revenue of $91.6 million to $93.1 million, GAAP diluted earnings per share of $1.90 to $1.94, and non-GAAP diluted earnings per share of $2.07 to $2.11.
The Company’s non-GAAP diluted earnings per share guidance excludes stock-based compensation expense, net of tax expense. The Company expects stock-based compensation expense, net of tax, to be approximately $2.5 million and $0.6 million for the full year and third quarter of 2026, respectively.
Presentation of Amounts
Amounts discussed in this press release are presented in millions, rounded to one decimal place, and amounts in the accompanying financial tables are presented in thousands, except per share data. Percentage changes are calculated using the amounts in thousands presented in the tables, and per share amounts are calculated using unrounded amounts. As a result, percentages recalculated using the rounded amounts in millions may differ from those presented.

Use of Non-GAAP Financial Measures
The Company believes using non-GAAP net income, non-GAAP net income per share-diluted, and free cash flow is helpful to our investors. These measures, which we refer to as our non-GAAP financial measures, are not prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). These non-GAAP measures are intended to provide the reader with additional supplemental perspectives on operating results, performance trends, and financial condition. Non-GAAP financial measures are not a substitute for GAAP measures; they should be read and used in conjunction with the Company’s GAAP financial information. Because non-GAAP financial measures presented in this release are not measurements determined in accordance with GAAP and are susceptible to varying calculations, these non-GAAP financial measures, as presented, may not be comparable to other similarly titled measures presented by other companies.
We calculate non-GAAP net income as net income excluding:
(1)Stock-based compensation expense, net of tax. Because of varying available valuation methodologies, subjective assumptions, and the variety of equity instruments that can impact a company’s non-cash expenses, we believe that providing non-GAAP financial measures that exclude stock-based compensation expense allows for meaningful comparisons between our operating results from period to period;
(2)Operating expenses, net of tax, that we believe are not indicative of the Company’s ongoing core operating performance; and
(3)Infrequent income tax items are considered based on their nature and are excluded from the provision for income taxes as these costs or benefits are not indicative of our normal or future provision for income taxes.
We calculate free cash flow as net cash provided by operating activities, less net cash used in investing activities for the development of internal software and purchases of property and equipment.
We consider free cash flow to be a liquidity measure that provides useful information to management and investors about the amount of cash generated by our business that can be used for strategic opportunities, including investing in our business, making strategic acquisitions, strengthening our balance sheet and returning cash to our stockholders through various means.


Our non-GAAP financial measures are important tools for financial and operational decision-making and for evaluating our ongoing core operating results.
A reconciliation of the non-GAAP financial measures used in this release to the most comparable GAAP measures for the respective periods can be found in the table later in this release immediately following the condensed statements of
operations. These non-GAAP financial measures should not be considered in isolation or as a substitute for a measure of the Company’s operating performance or liquidity prepared in accordance with GAAP and are not indicative of net income or cash provided by operating activities.
Conference Call
The Company has scheduled a conference call to discuss this release beginning at 11:00 a.m. Eastern Time, October 30, 2026. Individuals interested in listening to the conference call may do so by registering here, https://register-conf.media-server.com/register/BI7e9cb633a38e45258f691f2b6d592419

Once registered, a dial-in number, a unique PIN, and instructions will be provided to participants.

The conference call will also be available in real-time via the Internet at http://www.iradimed.com/en-us/investors/events/. A recording of the call will be available on the Company’s website following the call's completion.

About IRADIMED CORPORATION
IRADIMED CORPORATION is a leader in developing innovative Magnetic Resonance Imaging (“MRI”) compatible medical devices. We design, manufacture, market, and distribute MRI-compatible medical devices, accessories, disposables, and related services.
We are the only known provider of a non-magnetic intravenous (“IV”) infusion pump system specifically designed to be safe for use during MRI procedures. We were the first to develop an infusion delivery system that largely eliminates many of the dangers and problems present during MRI procedures. Standard infusion pumps contain magnetic and electronic components that can create radio frequency interference and are dangerous to operate in the presence of the powerful magnet that drives an MRI system. Our patented MRidium® MRI compatible IV infusion pump systems (3860 and 3870) have a non-magnetic ultrasonic motor, uniquely designed non-ferrous parts, and other special features to safely and predictably deliver anesthesia and other IV fluids during various MRI procedures. Our pump solutions provide a seamless approach that enables accurate, safe, and dependable fluid delivery before, during, and after an MRI scan, which is essential to critically ill patients who cannot be removed from their vital medications and children and infants who must generally be sedated to remain immobile during an MRI scan.
Our 3880 MRI compatible patient vital signs monitoring system has been designed with non-magnetic components and other special features to safely and accurately monitor a patient’s vital signs during various MRI procedures. The Iradimed 3880 system operates dependably in magnetic fields up to 30,000 gauss, which means it can operate virtually anywhere in the MRI scanner room. The Iradimed 3880 has a compact, lightweight design, allowing it to travel with the patient from the critical care unit to the MRI and back, resulting in increased patient safety through uninterrupted vital signs monitoring and decreasing the amount of time critically ill patients are away from critical care units. The features of the Iradimed 3880 include wireless ECG with dynamic gradient filtering; wireless SpO2 using Masimo® algorithms; non-magnetic respiratory CO2; invasive and non-invasive blood pressure; patient temperature, and optional advanced multi-gas anesthetic agent unit featuring continuous Minimum Alveolar Concentration measurements. The Iradimed 3880 MRI compatible patient vital signs monitoring system has an easy-to-use design and allows for the effective communication of patient vital signs information to clinicians.
For more information, please visit www.iradimed.com.


Forward-Looking Statements
This release and any oral statements made regarding the subject of this release contain forward-looking statements as defined under Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are intended to be covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, that address activities that the Company assumes, plans, expects, believes, intends, projects, indicates, estimates or anticipates (and other similar expressions) will, should or may occur in the future are forward-looking statements, including statements relating to financial guidance, future quarterly cash dividends, operational issues meeting demand, commercialization, timing and expected revenue ramping of our next-generation 3870 MRI compatible IV infusion pump, and the Company’s strategic plans, objectives, and intentions. The forward-looking statements are based on management’s current belief, based on currently available information, as to the outcome and timing of future events. The forward-looking statements involve risks and uncertainties, including, among others, that our business plans may change as circumstances warrant.

Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date that they are made, which reflect management’s current estimates, projections, expectations, or beliefs, and which involve
risks and uncertainties that could cause actual results and outcomes to be materially different. Risks and uncertainties that may affect the future results of the Company include, but are not limited to: our ability to obtain or maintain regulatory approvals and comply with applicable regulations, including 510(k) clearances for our products and product candidates, the outcome of inspections conducted by the U.S. Food & Drug Administration (the “FDA”) or other regulatory bodies, additional actions by or requests from the FDA or other regulatory bodies, and unanticipated costs or delays associated with the resolution of such matters; our reliance on a limited number of products and our ability to identify and pursue development of additional products; our ability to retain key management, marketing and scientific personnel, and to attract and retain additional qualified personnel; our expectations regarding the sales and marketing of our products and services; our expectations regarding the integrity of our supply chain; the potential for adverse application of applicable laws and regulations on our operations; our expectations for market acceptance of our new products; the potential for exposure to product liability claims and our marketed products to be withdrawn due to recalls or adverse events; our ability to prepare, file, prosecute, maintain, defend against infringement of, and enforce patent claims and other intellectual property rights on our products; the implementation of our business strategies; our financial performance and how it may be interpreted by securities analysts and investors; our ability to compete with existing competitors and new market entrants; difficulties or delays in developing, manufacturing, or marketing our products and services; changes in laws or in their interpretation or application, and the risk of non-compliance; cost-containment efforts of our customers, purchasing groups, third-party payers and governmental organizations; costs associated with protecting our trade secrets and enforcing our patent, copyright and trademark rights, including the risk of successful challenges to the validity of such rights; costs or claims resulting from errors or defects in our manufacturing that may injure persons or damage property, including costs from remediation efforts or recalls; the results or timing of any commercial disputes, patent infringement claims, other legal proceedings, or government investigations; interruptions in our ability to manufacture our products, or the unavailability or increased cost of key components or raw materials; the risk that third parties may fail to meet their contractual obligations, which could disrupt our operations or adversely affect our financial results; the effects of government-mandated healthcare reform; the impact on our operations and financial results of public health emergencies, including natural disasters, and policies and actions by governments or other third parties; breaches or failures of our or our vendors’ or customers’ information technology systems, including by cyberattack, data leakage, or unauthorized access; the risks associated with the integration of artificial intelligence (“AI”) or machine learning (“ML”) into our products or business, including algorithmic errors or bias, uncertain regulatory requirements applicable to AI-enabled medical devices, data privacy and security concerns arising from the use of AI or ML, and potential liability arising from AI-driven product decisions or recommendations; the loss of one or more key customers or suppliers, or a default by any such party; unfavorable changes to the terms of key customer or supplier relationships; weakening of economic conditions that could adversely affect demand for our products; changes in tax rates, interest rates or inflationary pressures on the U.S. and global economies; geopolitical risks, including international conflicts and political instability, which could lead to increased market volatility; and other risks detailed in our filings with the United States Securities and Exchange Commission (the “SEC”). You should consider the forward-looking statements contained in this press release in light of the risk factors and other information set forth under Part I, Item 2, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and Part II, Item 1A, “Risk Factors” of the Company’s Quarterly Reports on Form 10-Q, and Part I, Item 1A, “Risk Factors” of the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as well as those otherwise described or updated from time to time in our other filings with the SEC. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made, and the Company undertakes no commitment to publicly update or revise the forward-looking statements, whether as a result of new information, future developments, or otherwise, except as required by applicable law.


IRADIMED CORPORATION
CONDENSED BALANCE SHEETS
(in thousands)

September 30,December 31,
20262025
(unaudited)(audited)
ASSETS
Current assets:
Cash and cash equivalents$63,288$51,159
Other current assets29,51230,044
Total current assets92,80081,203
Property and equipment, net24,07623,856
Other assets4,1943,717
Total assets$121,070$108,776
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable$2,419$1,820
Deferred revenue3,5722,871
Other current liabilities4,3325,489
Total current liabilities10,32310,180
Deferred revenue, non-current4,2933,978
Total liabilities14,61614,158
Stockholders’ equity:
Total stockholders’ equity106,45494,618
Total liabilities and stockholders’ equity$121,070$108,776


IRADIMED CORPORATION
CONDENSED STATEMENTS OF OPERATIONS
(Unaudited)
(in thousands, except per share data)

Three Months Ended
September 30,		Nine Months Ended
September 30,
2026202520262025
Revenue$24,203 $21,202 $66,648 $61,122 
Cost of revenue5,747 4,708 16,219 13,830 
Gross profit18,456 16,494 50,429 47,292 
Operating expenses:
General and administrative4,533 4,356 12,967 13,246 
Sales and marketing4,909 4,631 13,207 12,817 
Research and development875 674 2,489 2,176 
Total operating expenses10,317 9,661 28,663 28,239 
Income from operations8,139 6,833 21,766 19,053 
Other income, net529 464 1,559 1,517 
Income before provision for income taxes8,668 7,297 23,325 20,570 
Provision for income tax expense2,162 1,721 5,783 4,532 
Net income$6,506 $5,576 $17,542 $16,038 
Net income per share:
Basic$0.51 $0.44 $1.37 $1.26 
Diluted$0.51 $0.43 $1.37 $1.25 
Weighted average shares outstanding:
Basic12,78712,72112,78412,717
Diluted12,87712,86012,87312,842


IRADIMED CORPORATION
RECONCILIATION OF NON-GAAP FINANCIAL MEASURES
(Unaudited)
(in thousands, except per share data)

Non-GAAP Net Income and Diluted EPS
Three Months Ended
September 30,		Nine Months Ended
September 30,
2026202520262025
Net income$6,506 $5,576 $17,542 $16,038 
Excluding:
Stock-based compensation expense, net of tax benefit616 527 1,799 1,760 
Non-GAAP net income$7,122 $6,103 $19,341 $17,798 
Weighted-average shares outstanding – diluted12,877 12,860 12,873 12,842 
Non-GAAP net income per share – diluted$0.55 $0.47 $1.50$1.39
Non-GAAP Free Cash Flow
Three Months Ended
September 30,		Nine Months Ended
September 30,
2026202520262025
Net cash provided by operating activities$6,996 $6,986 $21,227 $19,025 
Less:
Capital Expenditures212 1,264 
1
1,124 8,005 
1
Free cash flow$6,784 $5,722 $20,103 $11,020 
1 For the three and nine months ended September 30, 2025, capital expenditures include approximately $1.3 million and $6.8 million respectively, related to the construction of a new corporate office and manufacturing facility completed in 2025.
Media Contact:
IRADIMED CORPORATION
(407) 677-8022
InvestorRelations@iradimed.com

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

4 documents

Press Releases

Other Documents

Keep reading

More on IRMD

All IRMD news

Trending in the feed

VLO
Valero to Acquire Former Houston Refinery from LyondellBasell Open the live feed